MBX BIOSCIENCES INC (MBX) competitors & alternatives
Health Care · NASDAQ
MBX BIOSCIENCES INC (MBX)'s top competitors and alternatives — its most similar public companies — include CULLINAN THERAPEUTICS INC (CGEM), Odyssey Therapeutics, Inc. (ODTX), BIOCRYST PHARMACEUTICALS INC (BCRX), Seaport Therapeutics, Inc. (SPTX), ACLARIS THERAPEUTICS INC (ACRS), LEXEO THERAPEUTICS INC (LXEO), Indaptus Therapeutics, Inc. (INDP), ALPHA TEKNOVA INC (TKNO), AGENUS INC (AGEN), NAUTILUS BIOTECHNOLGY INC (NAUT), WHITEHAWK THERAPEUTICS INC (WHWK) and Bio-Techne (TECH). These are MBX BIOSCIENCES INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top MBX competitors & alternatives
-
CULLINAN THERAPEUTICS INCCGEMHealth Care
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases.
$17.65 (as of 2026-07-22) · market cap $1.1B
-
Odyssey Therapeutics, Inc.ODTXHealth Care
A clinical-stage biotechnology company developing a pipeline of novel small molecule and protein therapeutic candidates.
$18.61 (as of 2026-07-22) · market cap $865M
-
BIOCRYST PHARMACEUTICALS INCBCRXHealth Care
BioCryst Pharmaceuticals is a biotech company focused on commercializing and developing innovative therapies for hereditary angioedema and other rare diseases…
$9.51 (as of 2026-07-22) · market cap $2.4B
-
Seaport Therapeutics, Inc.SPTXHealth Care
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics using its proprietary drug development platform.
$21.30 (as of 2026-07-22) · market cap $1.1B
-
ACLARIS THERAPEUTICS INCACRSHealth Care
Aclaris Therapeutics is a clinical-stage biopharmaceutical firm developing a pipeline of novel treatments for immuno-inflammatory diseases through a strategy…
$5.62 (as of 2026-07-22) · market cap $778M
-
LEXEO THERAPEUTICS INCLXEOHealth Care
Lexeo is a clinical-stage genetic medicine company developing gene therapies targeting the genetic root causes of rare cardiovascular diseases like Friedreich…
$4.87 (as of 2026-07-22) · market cap $365M
-
Indaptus Therapeutics, Inc.INDPHealth Care
A clinical-stage biotechnology company currently evaluating strategic options and potential business combinations to maximize shareholder value.
$2.64 (as of 2026-07-22) · market cap $300M
-
ALPHA TEKNOVA INCTKNOHealth Care
Alpha Teknova is a specialized manufacturer of essential reagents and custom chemical solutions that accelerate the development and production of…
$5.24 (as of 2026-07-22) · market cap $281M
-
AGENUS INCAGENHealth Care
A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term…
$5.53 (as of 2026-07-22) · market cap $232M
-
NAUTILUS BIOTECHNOLGY INCNAUTHealth Care
A pre-commercial proteomics platform company developing Iterative Mapping technology to enable single-molecule protein counting for comprehensive, reproducible…
$1.70 (as of 2026-07-22) · market cap $216M
-
WHITEHAWK THERAPEUTICS INCWHWKHealth Care
Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload…
$3.99 (as of 2026-07-22) · market cap $216M
-
Bio-TechneTECHHealth Care
A leading life sciences company providing essential reagents, analytical tools, and bio-manufacturing solutions for research and clinical diagnostics.
$71.78 (as of 2026-07-22) · market cap $11.2B
Not quite? Describe exactly what you want →
Peers are MBX BIOSCIENCES INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: MBX BIOSCIENCES INC (MBX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.